Research highlight

Adv. Mater. 2017
관리자 2018.01.11
365 Adveanced materials.png  

Magnetic fluid hyperthermia has been recently considered as a Renaissance of cancer treatment modality due to its remarkably low side effects and high treatment efficacy compared to conventional chemotheraphy or radiotheraphy. However, insufficient AC induction heating power at a biological safe range of AC magnetic field (Happl·fappl < 3.0 ~ 5.0 x 109 Am-1s-1), and highly required biocompatibility of superparamagnetic nanoparticle (SPNP) hyperthermia agents are still remained as critical challenges for successful clinical hyperthermia applications. Here, we report our newly developed highly biocompatible magnesium shallow doped g-Fe2O3 (Mg0.13-gFe2O3) SPNPs with exceptionally high intrinsic loss power (ILP) in a range of 14 nHm2kg-1, which is a ~100 times higher than that of commercial Fe3O4 (Feridex, ILP = 0.15 nHm2kg-1) at Happl·fappl = 1.23 x 109Am-1s-1. The significantly enhanced heat induction characteristics of Mg0.13-gFe2O3 were primarily due to the dramatically enhanced out-of-phase magnetic susceptibility and magnetically-tailored AC/DC magnetic softness resulted from the systematically controlled Mg2+ cations distribution and concentrations in octahedral site Fe vacancies of g-Fe2O3 instead of well know Fe3O4 SPNPs. In-vitro and in-vivo magnetic hyperthermia studies usingMg0.13-gFe2O3 nanofluids were conducted to estimate bioavailability and biofeasibility. Mg0.13-gFe2O3 nanofluids showed promising hyperthermia effects to completely kill the tumors.


Advanced Materials, 2017, 1704362